All In Biotech

Drug Trial Radar · NCT06726161

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC

Phase 1/2 Randomized, Controlled, Open-label Trial of Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ Unresectable Hepatocellular Carcinoma (HCC)

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 590 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

590

Planned (sponsor's estimate)

Start

Sep 5, 2025

Primary completion

Jun 2030

Study completion Jun 2031

Sponsor

Lead sponsor
RayzeBio, Inc.Industry
Sponsor type
Industry
First posted
Dec 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1/2 randomized, controlled, open-label trial of theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable hepatocellular carcinoma (HCC)

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

  • RYZ811Diagnostic test

    Ga-68

  • RYZ801Drug

    Ac-225

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Therapeutic - RYZ801Time frame: Rate of DLTs during the first 42 days of study treatment
  2. Therapeutic - RYZ801Time frame: From enrollment for up to three months or study discontinuation, whichever occurs first.
  3. Therapeutic - RYZ801Time frame: From enrollment to 3months after randomization or study discontinuation, whichever occurs first.
  4. Diagnostic - RYZ811Time frame: Baseline, pre-injection and post-injection up to 6 days post injection.
  5. Diagnostic - RYZ811Time frame: RYZ811 biodistribution to be assessed on the day of injection.

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Research Facility

    Birmingham, Alabama · Recruiting

  • Research Facility

    Phoenix, Arizona · Recruiting

  • Research Facility

    Orange, California · Recruiting

  • Research Facility

    Jacksonville, Florida · Recruiting

  • Research Facility

    Lexington, Kentucky · Recruiting

  • Research Facility

    Baltimore, Maryland · Recruiting

  • Research Facility

    Rochester, Minnesota · Recruiting

  • Research Facility

    St Louis, Missouri · Recruiting

  • Research Facility

    Omaha, Nebraska · Recruiting

  • Research Facility

    New York, New York · Recruiting

  • Research Facility

    Houston, Texas · Recruiting

  • Research Facility

    Charlottesville, Virginia · Recruiting

  • Research Facility

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.